文献速递淋巴瘤

1972例弥漫大B细胞淋巴瘤患者继发性中枢神经系统淋巴瘤的发生率与特征:丹麦全国队列研究

Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study.
PubMed 文献 · Blood Adv · 2025-01-01

该丹麦全国队列研究纳入1972例弥漫大B细胞淋巴瘤(DLBCL)患者,采用竞争风险模型计算继发性中枢神经系统淋巴瘤(SCNSL)累积发生率,并用病因特异性Cox模型分析危险因素。68例(3.4%)在首次复发时发生SCNSL,1年和2年粗累积发生率分别为2.0%和2.6%;结外(EN)部位数量和位置是最显著的预测因素,SCNSL后中位总生存(OS)仅3.2个月。

要点

  • 1972例DLBCL中68例(3.4%)首次复发时发生SCNSL。
  • 1年和2年SCNSL粗累积发生率分别为2.0%和2.6%。
  • 高危CNS-IPI患者1年和2年累积发生率分别为6.4%和7.5%。

核心结论

  • 基于竞争风险调整的真实世界全国人群数据显示,首次复发时SCNSL的发生率低于既往报告,结外部位数量和位置是最显著的SCNSL预测因素。

研究设计与样本

  • 丹麦全国队列研究,纳入1972例DLBCL患者,以死亡或无SCNSL复发为竞争风险计算SCNSL发生率,采用病因特异性Cox比例风险模型识别SCNSL相关危险因素。

主要发现

  • 1972例DLBCL患者中68例(3.4%)在首次复发时发生SCNSL。
  • SCNSL的1年和2年粗累积发生率分别为2.0%(95%CI 1.5-2.7)和2.6%(95%CI 2.0-3.4)。
  • 高危CNS-IPI评分患者的1年和2年累积发生率分别为6.4%和7.5%。
  • 与SCNSL风险增加相关的特定结外部位为骨髓、心脏、肾脏/肾上腺、卵巢、睾丸和子宫。
  • SCNSL后中位总生存(OS)为3.2个月。

关键数值与推荐

  • SCNSL的1年粗累积发生率为2.0%(95%CI 1.5-2.7),2年为2.6%(95%CI 2.0-3.4)。
  • 高危CNS-IPI评分患者1年累积发生率为6.4%,2年为7.5%。
  • 治疗结束(EOT)后6个月内发生的SCNSL与更高的基线CNS-IPI评分及更差的OS相关,相比EOT后超过6个月发生的SCNSL。
  • 低危CNS-IPI合并晚发型SCNSL的患者预后最好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary central nervous system lymphoma (SCNSL) is a rare manifestation of diffuse large B-cell lymphoma (DLBCL) with a poor prognosis. We present updated data from a nationwide study on the incidence and clinical characteristics of SCNSL. The incidence of SCNSL was calculated considering death or relapse without SCNSL as competing risks. Risk factors associated with SCNSL were identified using a cause-specific Cox proportional hazards model. A total of 1972 patients with DLBCL were included, of which 68 (3.4%) experienced SCNSL at the first relapse. The crude 1- and 2-year cumulative incidence of SCNSL was 2.0% (95% confidence interval [CI], 1.5-2.7) and 2.6% (95% CI, 2.0-3.4), respectively. For patients with a high-risk central nervous system international prognostic index (CNS-IPI) score, the 1- and 2-year cumulative incidence was 6.4% and 7.5%, respectively. The number and location of extranodal (EN) sites were the most significant predictors of SCNSL. Specific EN sites associated with an increased risk were the bone marrow, heart, kidneys/adrenal glands, ovaries, testes, and uterus. The median overall survival (OS) after SCNSL was 3.2 months. SCNSL within 6 months after the end of treatment (EOT) was associated with a higher baseline CNS-IPI score and worse OS than SCNSL >6 months after EOT. Patients with a combination of low-risk CNS-IPI and late-onset SCNSL had the most favorable prognosis. In conclusion, updated real-world population-based data on SCNSL at first relapse, adjusted for competing risks, demonstrated a lower incidence of SCNSL than previously reported, with the number and location of EN sites being the most significant predictors of SCNSL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Tolley ER, Nielsen TH, Hersby DS, et al. Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study. Blood Adv. 2025. PMID: 39571170. doi:10.1182/bloodadvances.2024014404

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。